Immatics (NASDAQ:IMTX – Get Rating) – Stock analysts at Jefferies Financial Group lowered their FY2026 earnings estimates for Immatics in a report issued on Thursday, November 17th. Jefferies Financial Group analyst K. Shi now anticipates that the company will earn $1.10 per share for the year, down from their prior forecast of $1.26. The consensus estimate for Immatics’ current full-year earnings is $0.42 per share.
Separately, Chardan Capital reduced their target price on shares of Immatics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, August 10th.
Immatics Price Performance
IMTX opened at $10.55 on Monday. The company has a 50 day simple moving average of $10.50 and a two-hundred day simple moving average of $9.86. Immatics has a 1-year low of $5.75 and a 1-year high of $14.00. The firm has a market cap of $804.19 million, a P/E ratio of 15.75, a PEG ratio of 2.89 and a beta of 0.48.
Hedge Funds Weigh In On Immatics
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Immatics during the 1st quarter worth approximately $27,000. Point72 Asset Management L.P. purchased a new position in Immatics during the 3rd quarter worth approximately $2,306,000. Wolverine Asset Management LLC raised its position in Immatics by 49.0% during the 3rd quarter. Wolverine Asset Management LLC now owns 7,231 shares of the company’s stock worth $72,000 after buying an additional 2,377 shares during the last quarter. TD Asset Management Inc. acquired a new stake in Immatics in the 3rd quarter valued at $195,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Immatics in the 3rd quarter valued at $402,000. 34.12% of the stock is owned by hedge funds and other institutional investors.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immatics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Immatics wasn’t on the list.
While Immatics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
